Zacks Investment Research Reiterates “Sell” Rating for Yield10 Bioscience (NASDAQ:YTEN)

Yield10 Bioscience (NASDAQ:YTEN)‘s stock had its “sell” rating reaffirmed by Zacks Investment Research in a research report issued on Saturday, reports.

According to Zacks, “Yield10 Bioscience, Inc. is an agricultural bioscience company. It focuses on the development of disruptive technologies for improvement in crop yield to enhance global food security. The company is working on new approaches, to improve fundamental elements of plant photosynthetic efficiency and optimizing carbon metabolism for better production. It operates primarily in Saskatoon, Saskatchewan, Canada. Yield10 Bioscience, Inc., formerly known as Metabolix, Inc., is based in Woburn, Massachusetts. “

Several other equities analysts have also commented on the stock. Aegis reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Yield10 Bioscience in a research report on Tuesday, August 13th. National Securities reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Yield10 Bioscience in a research report on Tuesday, August 20th.

Shares of NASDAQ:YTEN traded down $0.05 during trading on Friday, reaching $0.64. The stock had a trading volume of 55,457 shares, compared to its average volume of 67,712. Yield10 Bioscience has a one year low of $0.50 and a one year high of $1.77. The company has a market capitalization of $8.64 million, a P/E ratio of -0.69 and a beta of 3.15. The company has a current ratio of 3.33, a quick ratio of 3.33 and a debt-to-equity ratio of 1.17. The firm’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.90.

Yield10 Bioscience (NASDAQ:YTEN) last announced its quarterly earnings data on Monday, August 12th. The specialty chemicals company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.06. The firm had revenue of $0.32 million during the quarter. Yield10 Bioscience had a negative net margin of 1,320.21% and a negative return on equity of 145.61%. Equities research analysts forecast that Yield10 Bioscience will post -0.66 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Renaissance Technologies LLC boosted its holdings in shares of Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 478,176 shares of the specialty chemicals company’s stock after buying an additional 41,500 shares during the quarter. Renaissance Technologies LLC owned 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 7.69% of the company’s stock.

Yield10 Bioscience Company Profile

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.

Read More: Intrinsic Value

Get a free copy of the Zacks research report on Yield10 Bioscience (YTEN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with's FREE daily email newsletter.